On October 30, HRSA announced that it had selected eight drug manufacturers to participate in its 340B Rebate Model Pilot Program, spanning 10 drugs representing a range of widely used therapies. These include:
Latest Post
More Posts
HRSA’s 340B Rebate Pilot Program: Industry Debates, Congressional Response, and Program Implications
HRSA Launches and Seeks Comments on 340B Rebate Model Pilot Program
HRSA Announces New Requirements for FQHCs to Provide Insulin and Epinephrine at or below 340B Price
Federal District Court Upholds Authority of HHS to Pre-Approve 340B Rebate Programs; HRSA Submits Proposed 340B Rebate Guidance
FDA’s Semaglutide Shortage Resolution: Legal Implications and Risks for Compounding Pharmacies
